Inflammopharmacology最新文献

Treatment of biomedicine has advanced significantly in recent years, and it now has a very high success rate with severity of side effects making it so much more compelling to study emerging treatments. A broad concept is proposed, which pools in nominal antibiotics administration nutrition nutritional supplement if requisite and antibodies by maximizing the potential synergy of these elements, that is where conventional methods stop, this paradigm shift starts. The antibiotics act on the pathogen alone and when combined with therapeutic techniques results in increased recovery along with proper body defenses. The first-ever study of its kind combines antibody complex disguising as a carrier for the drugs which improves the palatability, extend retention in body and makes easy to store as well as distribute. This ground-breaking method could really alter the way digestive diseases is treated and provide an alternative to conventional methods.

In the dynamic realm of scientific inquiry, the identification and characterization of biologically active compounds derived from plant extracts have become of utmost significance. A particularly noteworthy flavonoid in this regard is aromadendrin (AMD), which can be found in a diverse range of foods, fruits, plants, and natural sources. The versatility of this compound is evident through its wide array of biological properties, including its well-documented anti-inflammatory, antioxidant, antidiabetic, neuroprotective, immunomodulatory, cardioprotective, and hepatoprotective effects. These diverse actions validate its potential utilization in addressing drug-related side effects, adverse reactions, neoplasms, ulcers, jaundice, diabetes mellitus, dermatitis, neurodegenerative diseases, cognitive disorders, polyploidy, carcinomas, common colds, and cumulative trauma disorders. This review aims to unlock the full potential of AMD and pave the way for groundbreaking advancements in the fields of medicine and nutrition. Prepare to embark on an enthralling journey as we unveil the hidden treasures and extraordinary prospects associated with AMD.

Glioblastoma multiforme (GBM), the fatal primary brain malignancy in adults, represents significant health challenges, and its eradication has been the ultimate goal of numerous medical investigations. GBM therapy encompasses various interventions, e.g., chemotherapy by synthetic cytotoxic agents like temozolomide (TMZ), radiotherapy, and, more recently, immunotherapy. A notable focus has been on incorporating naturally occurring substances in treating malignancies. Polyphenols and terpenoids, widely present in fruits and vegetables, constitute primary categories of agents employed for this purpose. They pose direct and indirect impacts on tumor growth and chemoresistance, mainly through impacting the phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling, crucial in cellular processes, metabolism, and programmed death. This paper thoroughly discusses the biologic effects and practical application of polyphenols and terpenoids on GBM through the PI3K/Akt/mTOR signaling in vitro and in vivo.

Post-herpetic neuralgia (PHN) is a type of neuropathic (nerve) pain that persists for more than 3 months after crusting of the last shingles lesion. It is difficult to relieve with analgesic/adjuvant medications, and so novel analgesics are needed. Our aim was to use a rat model of varicella zoster virus (VZV)-induced neuropathic pain to assess the pain relief efficacy of several small molecule angiotensin II type 2 (AT₂) receptor antagonists (PD123,319, EMA300, and EMA401) relative to clinically used analgesic/adjuvant agents from four different pharmacological classes. Male Wistar rats received a unilateral intraplantar injection of VZV-infected MRC-5 cells (2 × 10⁴ infected cells) and paw withdrawal thresholds (PWTs) in the ipsilateral hindpaws were assessed using von Frey filaments. Animals with PWTs ≤ 8 g received single doses of PD123,319 (0.03-3 mg/kg), EMA300 (0.3-5 mg/kg), EMA401 (0.03-1 mg/kg), gabapentin (10-60 mg/kg), amitriptyline (5-30 mg/kg), morphine (0.1-3 mg/kg), meloxicam (5-20 mg/kg) or vehicle and PWT versus time curves were generated. Single doses of PD123,319, EMA300, EMA401, gabapentin and morphine-evoked dose-dependent anti-allodynia in the hindpaws of VZV-rats. The mean (95% confidence intervals) ED₅₀s were 0.57 (0.04-1.7), 2.5 (1.0-3.7) and 0.41 (0.12-0.87) mg/kg for PD123,319, EMA300, and EMA401, respectively. The ED₅₀s for gabapentin and morphine were 39.9 (25.1-64.8) and 0.04 (0.16-2.09) mg/kg, respectively. In conclusion, the anti-allodynic efficacy of EMA401 in a VZV-rat model of neuropathic pain is aligned with its analgesic efficacy in a Phase 2a clinical trial in patients with PHN. This model has utility for anti-allodynic efficacy assessment of novel AT₂ receptor antagonists from drug discovery.

Probiotics (PBT) have been extensively studied as an adjunct therapy for various inflammatory conditions. This is because inflammation often leads to dysbiosis, a microbial imbalance that can be corrected using PBT. Most research has focused on Lactobacillus, with limited data on Bacillus PBT for alleviating CFA-induced arthritis in animal models. While most studies focus on the chronic aspect of CFA-induced arthritis, our current research aims to evaluate the effects of pre-treatment, concurrent treatment, and post-treatment with Bacillus subtilis (NMCC-path-14) against the acute phase of arthritis induced by CFA in the mice model. Arthritis was produced by administering CFA into the subplantar region of the mouse's right hind paw. Pain-related behavioral parameters, antioxidant capacity, histological and radiological parameters, expression of essential cytokines, and DNA damage were assessed during the acute phase. B. subtilis treatment significantly reduced the paw edema and improved the arthritic index. The nocifensive threshold was also raised, and muscle coordination improved considerably after B. subtilis treatment on days 7 and 14. The antioxidant capacity and histological and radiological parameters were also enhanced. We demonstrated that B. subtilis therapy preserved the DNA during the acute phase of arthritis using the Comet assay. Comparing results to the arthritic control, a significant reduction was observed in the expression levels of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and nuclear factor-kappa B (NF-κB). In contrast, the level of nuclear factor erythroid 2-related factor 2 (Nrf-2) was enhanced. During the acute phase of the disease, B. subtilis displayed a potent anti-inflammatory and anti-arthritic action against CFA-induced arthritis.

Introduction: Osteonecrosis usually occurs with necrotic bone exposure in the mandible asymptomatically for long periods but can evolve to present pain, fistula, odor, bleeding, and suppuration.

Objective: To evaluate the influence of cyclosporine treatment and its influence on osteonecrosis in a rat model.

Methods: The animals were randomly divided into 05 groups (n = 8/group). The negative control group (SAL), positive control group treated with zoledronic acid (ZA + SAL), and test groups were treated with cyclosporine A (CsA) at 5, 2.5, and 1.25 mg/kg and treated with ZA. The left lower second molars were extracted. The animals were euthanized 1 month after tooth extraction. Digital radiographs, histological slides, and immunoexpression of IL-2, IL-6, TNF-α, PPAR-γ, c-Fos, c-Jun, FoxP3, and INF-γ were analyzed. Western blot assays were performed to investigate the expression of RORyT. In addition, hematological analysis, body mass variation, and femur mechanical tests were performed.

Results: Radiographs showed that in the groups treated with ZA, there was an increase in the radiolucent area suggestive of osteonecrosis, and treatment with cyclosporine did not reduce this parameter (p < 0.001). In the western blot analysis, animals treated with ZA showed increased expression of RORyT (1.887 ± 0.114) compared to the saline group (0.799 ± 0.107), and treatment with the highest dose of cyclosporine (0.652 ± 0.070) reduced this expression (p < 0.001).

Discussion: Studies have observed bone health in animals treated with CsA. Treatment with this immunosuppressant showed a bone-protective effect of CsA, which corroborates our findings.

Conclusion: Treatment with CsA reduced the immunoexpression of pro-inflammatory cytokines such as IL-2 and TNF-α and decreased the expression of RORyT.

Objective: Knee osteoarthritis (KOA), predominantly affecting middle-aged and elderly populations, induces localized joint pain and functional impairment. It was to evaluate the effectiveness of acupotomy bone decompression (ABD) combined with sodium hyaluronate (SH) intra-articular injection on inflammatory responses in treating KOA.

Methods: Clinical data from 128 patients with KOA were retrospectively collected, categorized into SH group (n = 55) and ABD + SH group (n = 73). Pain was assessed using the visual analogue scale (VAS), knee joint function was evaluated, and knee joint balance and gait parameters were measured. The status of articular cartilage and bone marrow edema was evaluated using quantitative magnetic resonance imaging (MRI). Interleukin (IL)-6, IL-1β, tumor necrosis factor (TNF)-α, matrix metalloproteinase (MMP)-3, MMP-9, and hypersensitive C-reactive protein (hs-CRP) were detected.

Results: ABD + SH group showed drastic reductions in VAS scores, decreased indices of different axial balances, and increased stride length and walking speed versus the SH group (P < 0.05). Quantitative MRI examination revealed that relative to the SH group, ABD + SH group exhibited increased thickness of articular cartilage and reduced area of bone marrow edema post-treatment (P < 0.05). Post-treatment levels of hs-CRP, IL-6, IL-1β, TNF-α, MMP-3, and MMP-9 were markedly lower in the ABD + SH group versus SH group (P < 0.05). Moreover, the clinical effective rate in the ABD + SH group was drastically superior to the SH group (95.9% vs. 78.2%, P < 0.05).

Conclusion: Combining ABD with SH treatment for KOA effectively alleviates patient pain and inflammatory responses.